Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.15 - A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results

      00:00 - 00:00  |  Presenter: Matthew Lara

      • Abstract

      Loading...

  • +

    IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies

    • 13:15 - 14:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS05.01 - Welcome and Introductions

      13:15 - 13:20  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC

      13:20 - 13:35  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC

      13:35 - 13:50  |  Presenter: Alexander Spira

      • Abstract

      No abstract available for this presentation

    • +

      IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC

      13:50 - 14:05  |  Presenter: Afshin Dowlati

      • Abstract

      No abstract available for this presentation

    • +

      IS05.05 - Discussion

      14:05 - 14:15

      • Abstract

      No abstract available for this presentation

  • +

    ES20 - Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials*

    • 20:30 - 21:05
    • 9/14/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Education Session
    • Track: Immunotherapy (Phase II/III Trials)
    *Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.
    • +

      ES20.01 - The Statistical Imperatives of Immunotherapy Research

      20:30 - 20:32  |  Presenter: Mary Redman

      • Abstract

      No abstract available for this presentation

    • +

      ES20.02 - Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer

      20:32 - 20:34  |  Presenter: Sanjay Popat

      • Abstract

      Loading...

    • +

      ES20.03 - Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know

      20:34 - 20:36  |  Presenter: Nick Pavlakis

      • Abstract

      No abstract available for this presentation

    • +

      ES20.04 - Challenges to Expand Who Gets Immunotherapy

      20:36 - 20:38  |  Presenter: Lyudmila Bazhenova

      • Abstract

      No abstract available for this presentation

    • +

      ES20.05 - Live Discussion with Speakers

      20:38 - 21:05

      • Abstract

      No abstract available for this presentation